(AOF) – The Spineway Group announces the recent 510(k) clearance from the United States Food and Drug Administration (FDA) for its VEO posterior spinal fixation system. The specialist in innovative implants for the treatment of severe spinal pathologies (spine), specifies that this authorization, which allows the Group to market its VEOS system in the United States, “reinforces its strategic approach aimed at developing its activities in the American market.
The VEOS posterior spinal fixation system is intended to be “easy to use, fully modular”: it allows surgeons to perform interventions “in an open, minimally invasive and percutaneous (MIS) approach” for the treatment of a wide range of pathologies spinal, from degenerative spine to complex surgery and deformities.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.